BACKGROUND: Centers for Disease Control and Prevention guidelines recommend azithromycin or doxycycline for treatment of rectal chlamydial infection. METHODS: We created a retrospective cohort of male patients diagnosed as having rectal chlamydia between 1993 and 2012 at a sexually transmitted disease clinic in Seattle, Washington. Men were included in the analysis if they were treated with azithromycin (1 g single dose) or doxycycline (100 mg twice a day × 7 days) within 60 days of chlamydia diagnosis and returned for repeat testing 14 to 180 days after treatment. We compared the risk of persistent/recurrent rectal chlamydial infection among recipients of the 2 drug regimens using 4 follow-up testing time intervals (14-30, 60, 90, and 180 days). RESULTS: Of 1835 cases of rectal chlamydia diagnosed in the study period, 1480 (81%) were treated with azithromycin or doxycycline without a second drug active against Chlamydia trachomatis. Of these, 407 (33%) of 1231 azithromycin-treated men and 95 (38%) of 249 doxycycline-treated men were retested 14 to 180 days after treatment (P = 0.12); 88 (22%) and 8 (8%), respectively, had persistent/recurrent infection (P = 0.002). Persistent/recurrent infection was higher among men treated with azithromycin compared with doxycycline at 14 to 30 days (4/53 [8%] vs. 0/20 [0%]), 14 to 60 days (23/136 [17%] vs. 0/36 [0%]), and 14 to 90 days (50/230 [22%] vs. 2/56 [4%]). In multivariate analysis, azithromycin-treated men had a significantly higher risk of persistent/recurrent infection in the 14 to 90 days (adjusted relative risk, 5.2; 95% confidence interval, 1.3-21.0) and 14 to 180 days (adjusted relative risk, 2.4; 95% confidence interval, 1.2-4.8) after treatment. CONCLUSIONS: These data suggest that doxycycline may be more effective than azithromycin in the treatment of rectal chlamydial infections.
BACKGROUND: Centers for Disease Control and Prevention guidelines recommend azithromycin or doxycycline for treatment of rectal chlamydial infection. METHODS: We created a retrospective cohort of male patients diagnosed as having rectal chlamydia between 1993 and 2012 at a sexually transmitted disease clinic in Seattle, Washington. Men were included in the analysis if they were treated with azithromycin (1 g single dose) or doxycycline (100 mg twice a day × 7 days) within 60 days of chlamydia diagnosis and returned for repeat testing 14 to 180 days after treatment. We compared the risk of persistent/recurrent rectal chlamydial infection among recipients of the 2 drug regimens using 4 follow-up testing time intervals (14-30, 60, 90, and 180 days). RESULTS: Of 1835 cases of rectal chlamydia diagnosed in the study period, 1480 (81%) were treated with azithromycin or doxycycline without a second drug active against Chlamydia trachomatis. Of these, 407 (33%) of 1231 azithromycin-treated men and 95 (38%) of 249 doxycycline-treated men were retested 14 to 180 days after treatment (P = 0.12); 88 (22%) and 8 (8%), respectively, had persistent/recurrent infection (P = 0.002). Persistent/recurrent infection was higher among men treated with azithromycin compared with doxycycline at 14 to 30 days (4/53 [8%] vs. 0/20 [0%]), 14 to 60 days (23/136 [17%] vs. 0/36 [0%]), and 14 to 90 days (50/230 [22%] vs. 2/56 [4%]). In multivariate analysis, azithromycin-treated men had a significantly higher risk of persistent/recurrent infection in the 14 to 90 days (adjusted relative risk, 5.2; 95% confidence interval, 1.3-21.0) and 14 to 180 days (adjusted relative risk, 2.4; 95% confidence interval, 1.2-4.8) after treatment. CONCLUSIONS: These data suggest that doxycycline may be more effective than azithromycin in the treatment of rectal chlamydial infections.
Authors: Susan A Wang; John R Papp; Walter E Stamm; Rosanna W Peeling; David H Martin; King K Holmes Journal: J Infect Dis Date: 2005-02-11 Impact factor: 5.226
Authors: Charlotte K Kent; Janice K Chaw; William Wong; Sally Liska; Steven Gibson; Gregory Hubbard; Jeffrey D Klausner Journal: Clin Infect Dis Date: 2005-05-26 Impact factor: 9.079
Authors: A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema Journal: Antimicrob Agents Chemother Date: 1987-12 Impact factor: 5.191
Authors: William M Geisler; Jane S Hocking; Toni Darville; Byron E Batteiger; Robert C Brunham Journal: Clin Infect Dis Date: 2022-04-13 Impact factor: 9.079
Authors: Julia C Dombrowski; Michael R Wierzbicki; Lori M Newman; Jonathan A Powell; Ashley Miller; Dwyn Dithmer; Olusegun O Soge; Kenneth H Mayer Journal: Clin Infect Dis Date: 2021-09-07 Impact factor: 9.079